Free Daily Podcast Summary
HCPLive Podcasts: Daily Summaries Delivered
by HCPLive.com
Your destination feed for medical, health care and clinical science podcasts courtesy of HCPLive—featuring our shows Medical Ethics Unpacked, New Insight, and 5 Stories in Under 5.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 3 days ago42 min
4: Joint Ventures ACR 2026 Preview: 6 Abstracts Rheumatologists Should Watch
A recent episode of the Joint Ventures podcast previewed six abstracts for ACR Convergence 2026, held November 6 to 11 in Orlando, Florida. Hosts Jack Arnold, MBBS, PhD, academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, consultant rheumatologist at Freeman Hospital, Newcastle, each selected three from nearly 3,000 abstracts. Their picks span checkpoint inhibitor arthritis, psoriatic arthritis biomarkers, novel imaging, JAK inhibitor prescribing, and tissue-level B-cell depletion.
- 1 weeks ago26 min
3: Joint Ventures: Gout Management Gaps Persist Despite Effective Therapies, Guidelines
Gout remains poorly managed at the population level despite a well-understood pathophysiology, established serum urate targets, and an expanding pharmacological toolkit, according to a recent episode of the rheumatology podcast Joint Ventures. Hosts Jack Arnold, MBBS, PhD, academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, consultant rheumatologist at Freeman Hospital, Newcastle, reviewed current guidelines, emerging trial data, and the pipeline in gout management.
- Jul 16, 202642 min
2: Joint Ventures Recaps Influential EULAR Studies in SLE, RA, and More
In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD (academic clinical lecturer in rheumatology, University of Leeds), and Rihards Buss, MD (consultant rheumatologist, Freeman Hospital, Newcastle), record a post-EULAR 2026 debrief, working through the abstracts each identified as the meeting's most consequential. The conversation spans cellular therapies in autoimmune disease, proteomic biomarkers for treatment selection in RA, a landmark head-to-head trial in psoriatic arthritis, evolving classification criteria for axial spondyloarthritis, and the first phase III randomized controlled trial of a JAK inhibitor in polymyalgia rheumatica.Studies featured in this episode include: AB-101 Allogeneic NK Cell Therapy in Rheumatologic Diseases (LB0003) CARLYSLE: Obe-Cel CAR T in Severe Refractory SLE (OP0341) Ex Vivo Proteomic Signatures of JAK and TNF Inhibitors Predict Treatment Response in RA (OP048) BE BOLD: Bimekizumab vs Risankizumab in PsA (LB0001) 2025 ASAS-SPARTAN Revised AxSpA Classification Criteria (OP0236, OP0239, POS0190, POS1341) JAK-SPARE: Baricitinib in Early Polymyalgia Rheumatica (LB0005) Click here to read more and watch the full video at RheumatologyLive.
- Jul 9, 202642 min
1: Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B
Could hepatitis B finally have a finite treatment option? Tatyana Kushner, MD, joins hosts Nancy Reau, MD, and Kimberly Brown, MD, to break down the phase 3 B-Well data for bepirovirsen, the first agent to hit functional cure as a primary endpoint in chronic hepatitis B.The conversation covers the phase 3 B-Well 1 and B-Well 2 results, published in the New England Journal of Medicine and presented at EASL 2026, and why quantitative HBsAg testing is becoming essential to patient selection ahead of a potential approval. Kushner, Reau, and Brown also work through what functional cure actually means for patients, how it compares to spontaneous HBsAg loss, and what dosing and monitoring are likely to look like given signals for ALT elevation and renal effects seen in the trials. They discuss which patients are unlikely to be candidates, including those with cirrhosis or decompensated liver disease, and close with a look at what an approval could mean for hepatitis B screening rates and referral patterns between primary care and specialty hepatology.Bepirovirsen is not yet FDA approved. The FDA has accepted the New Drug Application for priority review, with a PDUFA goal date of October 26, 2026.For more: https://www.hcplive.com/view/liver-lineup-bepirovirsen-and-the-push-toward-functional-cure-in-hepatitis-b
- Jul 9, 202644 min
Liver Lineup: HDV Diagnosis, Bulevirtide, and the Delta Pipeline
In this episode of Liver Lineup: Updates and Unfiltered Insights, hosts Kimberly Brown, MD (Henry Ford Hospital), and Nancy Reau, MD (Rush University Medical Center), are joined by Tatyana Kushner, MD (Weill Cornell Medicine), to discuss hepatitis delta virus (HDV).Topics covered:Why fewer than 10% of HBsAg-positive patients have ever been tested for HDV — and why that needs to changeThe diagnostic cascade from HDV antibody to HDV RNA, and barriers to reflex testing implementationThe recent FDA approval of bulevirtide (Livdelzi) for chronic HDV infection, including dosing, administration, and the combination vs. monotherapy question10 mg vs. 2 mg dose considerations and off-treatment response dataPhase 3 pipelineFor more: https://www.hcplive.com/view/liver-lineup-hdv-diagnosis-bulevirtide-and-the-delta-pipeline
- Jun 26, 202613 min
Joint Ventures: Lupus Health Inequalities, Growing Burden of ICI-Arthritis at EULAR 2026
In this episode of Joint Ventures, host Rihards Buss, MD, consultant rheumatologist, Freeman Hospital, Newcastle, sits down with Sarah Dyball, MBBS, PhD, academic clinical lecturer, Centre for Musculoskeletal Research, University of Manchester, and Kate Harnden, MBChB, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, at the European Alliance of Associations for Rheumatology (EULAR) 2026 annual congress in London.Click here to watch the episode.
- Jun 24, 202613 min
Joint Ventures: CAR-T, Early Diagnosis Reshape Scleroderma at EULAR 2026
The therapeutic framework for systemic sclerosis is undergoing a fundamental reorientation, moving away from managing visible fibrotic sequelae toward targeting the autoantibody-driven mechanisms believed to initiate and propagate disease.On a recent episode of Joint Ventures recorded live at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress in London, host Jack Arnold, MBBS, PhD, of the University of Leeds, spoke with Vishal Kakkar, MD, also of the University of Leeds and a specialist in scleroderma, about the most consequential data emerging from the congress.Click here to watch the episode.
- Jun 24, 20267 min
Joint Ventures: Aiming for Targeted First-Line Therapy in Early RA at EULAR 2026
In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, academic clinical lecturer in rheumatology, University of Leeds, was joined at the European Alliance of Associations for Rheumatology (EULAR) 2026 annual congress in London by Laurence Duquenne, MD, a rheumatology researcher, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, an investigator on one of the meeting's standout studies to examine whether baseline naïve CD4+ T cell frequency can identify which newly diagnosed patients with rheumatoid arthritis (RA) are unlikely to respond to methotrexate monotherapy, and whether adding a biologic at the outset can close that gap.Click here to watch the episode.
Get HCPLive Podcasts summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases
Answers in CME
ICU Ed and Todd-Cast
Eddie and Todd
A Shot in the Arm Podcast
Ben Plumley
The Curbsiders Internal Medicine Podcast
Expert-led internal medicine discussions with clinical insights and humor for primary care and hospital medicine providers.
This Week in Cardiology
A weekly summary and analysis of key developments in cardiology for healthcare professionals.
JOSPT Insights
JOSPT
The VPZD Show
Two physicians discuss healthcare, medicine, and policy from a contrarian, middle-ground perspective.
Our Skin: A Personal Discovery Podcast
People share personal experiences with skin conditions like psoriasis and HS, discussing diagnosis, treatment, and living fully despite challenges.
Get Better Faster
Doctors and researchers discuss functional medicine and root-cause approaches to chronic illness and health optimization.
Red Pill Your Healthcast
Two healthcare providers discuss overlooked health issues and empower listeners to make informed decisions for their families.
Health vs Hype with the American Medical Association
A medical expert debunks viral health trends and misinformation with science-backed insights from physicians.
Made for Health | Peptides | Lyme | Chronic Infections | Long Covid | Insulin Resistance | Hypermobility
A physician explores science-based approaches to treating chronic conditions and restoring health.
About HCPLive Podcasts
Your destination feed for medical, health care and clinical science podcasts courtesy of HCPLive—featuring our shows Medical Ethics Unpacked, New Insight, and 5 Stories in Under 5.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from HCPLive Podcasts in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's HCPLive Podcasts daily summary?
It's a free AI-powered email that summarizes new episodes of HCPLive Podcasts as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the HCPLive Podcasts podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official HCPLive Podcasts product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by HCPLive.com.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts, any in the catalog. Basic raises that to 15, Pro to 40 and Max to 100. Browse our full catalog at /podcasts.
How often does HCPLive Podcasts release new episodes?
HCPLive Podcasts publishes daily. Our AI generates a summary within hours of each new episode.
What topics does HCPLive Podcasts cover?
HCPLive Podcasts covers topics including Science, News, Medicine, Fitness, Health & Fitness, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting HCPLive Podcasts summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.